FDA Advisory Committee Discusses J&J Booster

October 18, 2021

On Friday, an advisory committee to the FDA convened to discuss an additional dose of Janssen’s Johnson & Johnson (J&J) COVID-19 vaccine. The voting question was:

Do available data support the safety and effectiveness of Janssen COVID-19 Vaccine for use under EUA as a booster dose in individuals 18 years and older at least 2 months after a single dose primary vaccination?

The committee voted yes unanimously (19 to 0) in favor of a booster dose.

Panelists clarified that their recommendation will not change the primary series from one to two doses. A single dose is consistent with immunity; the second dose will be viewed as a booster to the primary series. Those who have just received one dose are still considered fully vaccinated in terms of efficacy in protecting against COVID-19. A second dose raises efficacy by boosting neutralizing antibody titers, as well as CD4 and CD8 responses. The Johnson & Johnson booster dose will measure the same as the primary series.

One argument in favor of a booster is to raise efficacy that parallels the efficacy ratings of Pfizer and Moderna’s vaccines. While the efficacy of one dose of Johnson & Johnson’s vaccine is lower than Moderna and Pfizer, a single dose still neutralizes COVID-19 and prevents severe disease. A single J&J vaccine also does not appear to show waning efficacy; rather, receiving a booster increases the efficacy on par with the Moderna and Pfizer vaccines. Efficacy ratings from a 30,000 patient study increased from 74% to 94% after the administration of a booster dose (in US participants).

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.